Climate Change in the Himalayas
Sanctuary Advisors LLC Makes New Investment in Pegasystems Inc. (NASDAQ:PEGA)
Climate Change in the HimalayasPetition launched calling for halt to expansion of Montreal-Trudeau airport due to noise and air pollution
Israeli attorney general orders probe into report that alleged Netanyahu’s wife harassed opponentsShyam Benegal is considered the pioneer of New Cinema or Parallel Cinema in India. Spawning from the efforts by Satyajit Ray and Mrinal Sen in Bengal, there was a new cinema developing beyond studio walls, in real locations and exteriors. There was an exciting combination of actors and non-actors, and the narratives were of social realism, of the intersections of class, caste and gender in historically grounded contexts. Moreover, the National Film Institute had trained a breed of new actors and technicians with exposure to the best international cinema. In this fertile ground stepped in a forty-year-old ad man, who planned a feature script written in his college days. Benegal’s Ankur (1974) told a little story about a crumbling feudal world and a peasant revolt, in which the landlord has an affair with the low caste servant girl and she falls pregnant. It was a story in which class, caste and gender identity were sharply implicated.The prolific storyteller made a series of films— Ankur , Nishant (1975), Manthan (1976), Mandi (1983)—giving voice to the subaltern, pulling focus on the shifting fabric of society, exploring the very dynamics of national change. I met Shyambabu in the Film Society circuit in Bombay, while I was teaching Film Studies and English at St. Xavier’s College. He would readily agree to do guest lectures with my students on cinema history and sometimes on his forthcoming films. When Suraj ka Satwan Ghoda (1992) released, I was fascinated with the film, and I made a presentation at the Prabhat Chitra Mandal (Film Society). Shyambabu was present and we had a long chat about the film that evening. Anil Dharker had liked my presentation and he carried an edited version of the paper in the Sunday Times the next week. I wrote several long essays on Shaymbabu’s films in Cinema in India edited by Khalid Mohamed. Within a few years, I was at the University of Sussex on a post-doctoral fellowship. I curated the India 50 conference and programmed Bhumika (1977) as one of the films to be screened. We invited Shyam Benegal to deliver a keynote, which was the highlight of the conference. He stayed with us in our London home and we binged on films as much as we could with frequent Chinese lunches in Chinatown, Soho. When the British Film Institute commissioned two films on Indian directors as part of their World Directors series, I was asked to write on Shyam Benegal while Rachel Dwyer wrote on Yash Chopra. The books were written within a short window. I had to fly out to Bombay, find all his films in the archives and then have long conversations with him. So for three weeks, we had morning and afternoon sessions in Shyambabu’s Tardeo office, punctuated with local lunch boxes or meals in his home hosted by his wife Nira Benegal. The Sahyadri Films office was meticulously organised and most of Shyambabu’s films—including his shorts and documentaries—were sourced from his own office. The book launch in London was at the Nehru Centre hosted by Girish Karnad, who was its director at that time. Shyambabu’s incisive understanding and analysis of history and socio-economic contexts allowed him to tell a layered and humane micro story, flanked by the macro canvas of larger forces of crucial socio-political changes. In a sense, he was a chronicler of our times, of post-colonial India, of promises delivered and failed. The first trilogy with Ankur , Nishant and Manthan were rural stories where the players were on the brink of change or instrumental in triggering change. The crop of film institute graduates quickly became part of the Benegal stable, a veritable gallery of dramatic actors, whose names had become synonymous with parallel cinema—Shabana Azmi, Naseeruddin Shah, Anant Nag, Pankaj Kapoor. There was Girish Karnad freshly returned from Oxford, who lived in Shyambabu’s home while he wrote his scripts. And Smita Patil, who was spotted by the director as a newreader on Doordarshan. These actors appear and reappear in his repertoire, exhibiting unique strengths and talents from film to film. While watching a restored version of Mandi during the recently concluded Festival of Three Continents in Nantes, one could see how Benegal was a conductor of an orchestra, drawing out a collective performance with an invisible baton. One of his strongest points was his ability to gather people and keep them in a repertory of films, while maintaining a democratic spirit in the unit. When Zubeidaa (2001) was being shot in Jaipur at Deegi Palace, the entire cast and crew had their meals together on a large table laid out in the palace garden. During the shoot for Mandi , the director set up volleyball courts, where everyone played till they were called in for their respective scenes. Shyambabu’s ouvre reveals an interesting alternation between narrative experimentation and social concern. His style of filmmaking placed him in the parallel cinema style, although he was impatient with such categorising of cinema. His restlessness with a linear narrative and his familiarity with literature has often led to delightful experiments in narrative style and craftsmanship as in Kondura (The Boon, 1977) or the masterful Suraj ka Satwan Ghoda . Greatly inspired by the life of Subhas Bose, his biopic on the controversial nationalist leader Bose: The Forgotten Hero (2005) or The Making of Mahatma (1996) were linear and structurally less interesting. Bhumika (1977), based on the autobiography of the Marathi actress Hansa Wadkar, significantly gave voice to an early woman performer, powered by a passionate Smita Patil in the best performance of her lifetime. Made during the rising women’s movement in India and the cultural reclaiming of women’s writings, this will remain as one of the director’s best works. The later trilogy of Mammo (1994), Sardari Begum (1995) and Zubeidaa (2001) were centred around Muslim women and the choices they make, all produced significantly after the Babri Masjid demolition and the Bombay riots. A firm believer in egalitarianism, Shyambabu’s socialist vision of post-colonial India is hugely influenced by Nehru, as evident in Bharat Ek Khoj (1988) for Doordarshan. Much later, when he served as nominated Member of Parliament, Rajya Sabha, he made the television series Samvidhaan (The Constitution, 2014). Constantly drawing upon voices from the margins, Benegal’s films articulate concerns about national identity, life on the periphery, gender/caste/class issues—from the peasant movement of the 1970s to the rural development drive and its conflicts to the untold stories of the handloom weaver, the low caste farmer and the performing woman. Benegal famously turned down his cousin Guru Dutt’s offer to assist him in his productions. He was convinced those were not the films he wanted to make. “People make films according to their own sensibility. The existing formal style was not suitable for me—I had no wish to work on design made films. Eventually though, all work is part of the same river.” Over the past two decades, every trip to the city of Bombay had involved a visit to Shyambabu’s office. During the 2021 pandemic, we witnessed the master helming a 200 strong unit shooting for the biopic Mujib: The Making of a Nation (2023) in Film City, where a large set had been designed for the Indo-Bangladesh co-production. Donning a cap in the hot sun, he would pace up and down the set and call the shots even as the sun set in the evening sky. After a tiring day’s shoot, he would still remember to call and ask if I had reached the airport in time, and whether I had dinner. Earlier this year, we were at his office sipping chai as he gave instructions to his assistant to play Mujib on the desktop. He was frail and he had to head home for lunch. Sure enough, he was back in an hour and got busy trying to arrange our lunch in the office. He was excited about screening Mujib in London. Last summer, we hosted a 50-year digital tribute session for Shyambabu with the London Indian Film Festival and my cultural outfit ‘Baithak’, UK. Several of his cast and colleagues joined us including Adoor Gopalakrishnan, Bina Paul, Naseeruddin Shah, Shabana Azmi, Nandita Das, Ila Arun, Nandita Puri, Atul Tiwari, Shantanu Moitra and his Mujib actor from Bangladesh, Arifin Shuvoo. Shyambabu was delightedly chatting with everybody and he happily announced “This calls for a party!” Finally there was a party on his 90 th birthday, when he was once again surrounded by his cast and crew members. He was on dialysis thrice a week but in office for regular hours, working on two different script ideas till the last day, wondering which one to start on first. We will miss Shyambabu, his energy, affection, empathy and humour. We will celebrate him, his boundless passion, dignity and never say die attitude. The biggest tribute to this giant filmmaker, knowledge sharer, philosopher, mentor will be for younger filmmakers to study his films and learn his language, enter his mind. He said to me, “I don’t know if cinema can actually bring about change in society. But cinema can certainly be a vehicle for creating social awareness. I believe in egalitarianism and every person’s awareness of human rights. Through my films I can say, here is the world, and here are the possibilities we have. It is difficult to define the purpose of my art...eventually it is to offer an insight into life, into experience, into a certain kind of emotive or cerebral area.” BY Apeksha Priyadarshini
Trump asks US Supreme Court to delay TikTok ban‘Cong to devote coming year for organisational revamp’WASHINGTON (AP) — Rep. of Maryland announced Monday that he will run to become the top Democrat on the powerful House Judiciary Committee next year, directly challenging fellow Democratic Rep. as the party prepares to fight a second Trump administration and an emboldened Republican majority. "House Democrats must stand in the breach to defend the principles and institutions of constitutional democracy," Raskin wrote in a letter to colleagues. “That is our historic assignment now. We dare not fail.” Raskin said in the letter — obtained by The Associated Press — that he decided to run for the post after spending the week consulting with House Democrats and “engaging in serious introspection” about where the party is following their stunning electoral defeat last month that handed Republicans control of Congress and the White House. While currently the top Democrat on the House Oversight Committee, Raskin said that come next year, the Judiciary Committee under his leadership would become "the headquarters of Congressional opposition to authoritarianism" as well as other efforts by President and his allies to thwart the Constitution. Being the face of the resistance against Trump is not new territory for Raskin who spent the last two years on Oversight as the most vocal defender of President and his family as they faced a sprawling Republican investigation — encouraged by Trump — into their various business affairs. Raskin, who is a former constitutional law professor, also helped draft articles of impeachment against the incoming president for his encouragement of the violent mob on Jan. 6, 2021, and led the impeachment prosecution in the Senate. But by throwing his hat in the ring, Raskin is inviting what a bitter intra-party fight with Nadler, who is currently serving his 17th term in Congress and who has held the top spot on Judiciary since 2019. Democrats have over the years rarely broken from the seniority system for committee assignments, no matter how long someone has held a position, making the outcome of the race uncertain. Both men did not respond to requests for comment but Raskin closed his letter by praising Nadler, saying that he made this decision “with respect and boundless admiration” for him. “If I’m lucky enough to be chosen for this responsibility in the 119th Congress, I will turn to Jerry first and throughout for his always wise counsel and political judgment,” Raskin added.
TEHRAN, Iran (AP) — Iran's government on Tuesday said it had lifted a ban on access to WhatsApp and Google Play after more than two years, the official IRNA news agency reported. Read this article for free: Already have an account? To continue reading, please subscribe: * TEHRAN, Iran (AP) — Iran's government on Tuesday said it had lifted a ban on access to WhatsApp and Google Play after more than two years, the official IRNA news agency reported. Read unlimited articles for free today: Already have an account? TEHRAN, Iran (AP) — Iran’s government on Tuesday said it had lifted a ban on access to WhatsApp and Google Play after more than two years, the official IRNA news agency reported. The report said the country’s Supreme Council of Cyber Space made the decision in a meeting led by reformist President Masoud Pezeshkian, who has vowed to remove restrictions on social media. Iran’s telecommunication minister Sattar Heshemi in a post on X called the decision a “first step” in removing restrictions and said “the path will continue” — indicating the possibility of unblocking other services. Many people reached by The Associated Press across the capital, Tehran, and other cities said they had access to the services on computers but not yet on mobile phones. WhatsApp has been the third most popular messaging platform in Iran after Instagram and Telegram. The ban on WhatsApp and Google Play was put in place in 2022 during mass protests against the government over the death of a woman held by the country’s morality police for allegedly violating the strictly enforced dress code. The protests calmed in 2023 after a crackdown by police and security forces that led to the death of hundreds of people and the imprisonment of thousands. Iran has blocked access to various social media platforms over the years but many people in the country use proxies and VPNs to access them. AdvertisementChristie's International Real Estate Has 100+ Affiliates in Almost 50 Countries and Territories Around the World and Maintains a Close Partnership with the Christie's Auction House @properties is the 8th Largest Residential Brokerage in the US by Sales Volume 1 Best-in-Class Title & Mortgage Offerings in Key Markets Will Also Be Included NEW YORK , Dec. 2, 2024 /PRNewswire/ -- Compass Inc. COMP ("Compass"), Christie's International Real Estate, and @properties have announced that they will be joining forces in a move to accelerate domestic and international growth opportunities. Christie's International Real Estate has global reach with a network of 100+ independently owned domestic and international Affiliates across 50 countries and territories. @properties is the 8th largest residential brokerage in the United States by sales volume, with operations in Greater Chicago, Indiana , Michigan , Wisconsin , and Metro Atlanta (through the Ansley Real Estate Brand). @properties' Northern California operation, under the Christie's International Real Estate Sereno brand, will become an independent brokerage while maintaining its network affiliation. Compass plans to continue to grow the independent affiliate network through the Christie's International Real Estate brand both domestically and internationally. "This partnership will allow us to empower strong independent brokerages and broker-owner entrepreneurs around the world who are Affiliates under Christie's International Real Estate," said Robert Reffkin , Compass Founder and CEO. "Our companies share the same passion for empowering entrepreneurial agents. Together, we will be able to provide unparalleled resources and support to help everyone succeed and deliver exceptional client experiences." "Compass shares our commitment to enhance the real estate industry through technology, marketing, and exceptional service and to embrace the local, independent broker through the Christie's International Real Estate and @properties brands," said Thad Wong , @properties Co-CEO. Mike Golden , @properties Co-CEO, added, "This is a very complementary union that respects our unique brands and empowers agents to provide an even better experience for the clients they serve." This addition will also include best-in-class title and mortgage businesses (namely, Proper Title and Proper Rate) as well as a lead-generation business (Suburban Jungle), which is in-line with Compass's long-term strategy to add high-margin services to its portfolio. Conference Call Details & Investor Materials Compass is hosting an investor conference call on Monday, December 2, 2024 , at 5 p.m. ET to discuss the transaction details. The conference call will be accessible via the Internet on the Compass Investor Relations website https://investors.compass.com . You can also access the audio webcast via the following link . Accompanying materials detailing the specifics of the transaction and a recording of the conference call will be available online under the SEC Filings and Events & Presentations sections of the Compass Investor Relations website: https://investors.compass.com . About Compass Compass is the largest residential real estate brokerage in the United States by sales volume 2 . Founded in 2012 and based in New York City , Compass provides an end-to-end platform that empowers its residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service, brokerage services and other critical functionality, all custom-built for the real estate industry. Compass agents utilize the platform to grow their business, save time and manage their business more effectively. For more information on how Compass empowers real estate agents, one of the largest groups of small business owners in the country, please visit www.compass.com . About @properties @properties is a Chicago -based real estate services company that owns and operates real estate brokerage firms in seven states, multi-state title and mortgage companies, Proper Title and Proper Rate, and the Christie's International Real Estate network. @properties is also the creator of pl@tformTM, a proprietary brokerage-technology software that enables agents to digitally manage all aspects of the client relationship and real estate transaction through one fully integrated system. Since its start in 2000, the company has been led by co-founders and co-CEOs, Thad Wong and Mike Golden . For more information, visit https://www.atproperties.com/ . About Christie's International Real Estate Christie's International Real Estate is a global luxury real estate network with over 100 independently owned brokerage Affiliates in almost 50 countries and territories. The brand is closely aligned with Christie's world-leading art and luxury business. Through the invitation-only network, Christie's International Real Estate and its members offer incomparable service to a global clientele of luxury homebuyers, sellers, developers, and investors. For more information, visit https://www.christiesrealestate.com/ . Disclosure Channels Compass uses its Investor Relations website, https://investors.compass.com , as a means of disclosing information which may be of interest or material to its investors and for complying with disclosure obligations under Regulation FD. We intend to announce material information to the public through filings with the Securities and Exchange Commission, or the SEC, the investor relations page on our website ( www.compass.com ), press releases, public conference calls, public webcasts, our X (formerly Twitter) feed (@Compass), our Facebook page, our LinkedIn page, our Instagram account, our YouTube channel, and Robert Reffkin's X (formerly Twitter) feed (@RobReffkin) and Instagram account (@robreffkin). Accordingly, investors should monitor each of these disclosure channels. Safe Harbor Statement This press release includes forward-looking statements, which are statements other than statements of historical facts, and statements in the future tense. These statements include, but are not limited to, statements regarding the proposed transaction, expected timeline, our expected future performance, including expected financial results, and our expectations for operational achievements and synergies after the closing of the proposed transaction. Forward-looking statements are based upon various estimates and assumptions, as well as information known to us as of the date of this press release, and are subject to risks and uncertainties, including but not limited to: our ability to consummate the proposed transaction on the expected timeline or at all (including due to inability to obtain the necessary regulatory approvals or obtaining such approvals subject to conditions that are not anticipated), the risk that a condition of closing of the proposed transaction may not be satisfied or that the closing of the proposed transaction might otherwise not occur, the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement, including in circumstances requiring us to pay a termination fee, the diversion of management time on transaction-related issues, risks related to disruption of management time from ongoing business operations due to the proposed transaction, the risk that the proposed transaction and its announcement could have an adverse effect on the ability of @properties to retain its key agents and personnel, unexpected costs, charges or expenses resulting from the proposed transaction, potential litigation relating to the proposed transaction that could be instituted against the parties to the merger agreement or their respective directors, managers or officers, including the effects of any outcomes related thereto and other risks set forth in our annual report on Form 10-K and our subsequent quarterly reports on Form 10-Q. Significant variation from the assumptions underlying our forward-looking statements could cause our actual results to vary, and the impact could be significant. Accordingly, actual results could differ materially from those predicted or implied or such uncertainties could cause adverse effects on our results. Reported results should not be considered as an indication of future performance. More information about factors that could adversely affect our business, financial condition and results of operations, or that could cause actual results to differ from those expressed or implied in our forward-looking statements is included under the captions "Risk Factors," "Legal Proceedings" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our most recent annual report on Form 10-K and our subsequent quarterly reports on Form 10-Q, copies of which are available on the Investor Relations page of our website at https://investors.compass.com/ and on the SEC website at www.sec.gov . All information herein speaks as of the date hereof and all forward-looking statements contained herein are based on information available to us as of the date hereof, and we do not assume any obligation to update these statements as a result of new information or future events. Undue reliance should not be placed on the forward-looking statements in this press release. Transaction Details The transaction is subject to customary closing conditions, including obtaining regulatory approvals, and is expected to close in 2025. Investors can find additional details on the transaction in Compass' investor presentation and Form 8-K filed with the SEC in conjunction with this press release. The 8-K and investor presentation are also available in the SEC Filings and Events & Presentations sections of the Compass Investor Relations website at https://investors.compass.com . 1 @properties was ranked the number eight real estate brokerage in sales volume for 2023 by Real Trends in March 2024 2 Compass was ranked the number one real estate brokerage in sales volume for 2023 by Real Trends in March 2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/compass-christies-international-real-estate-properties-and-ansley-real-estate-agree-to-join-forces-302320017.html SOURCE COMPASS © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE AmgenModernizing .NETpad: It’s a Wrap (Premium)
Grant Webster was in 2023 named Deloitte’s CEO of the year for navigating Tourism Holdings (Thl) through the pandemic and its aftermath. The company faced a tough year and although underlying earnings were up, net profit for the year ended June down 21% to $39.4m as vehicle sales stalled. How did the business perform in 2024? The year 2024 has been a challenging one operating in tough market conditions, but it has seen important ongoing steps in our transformation to being a global leader in the RV and tourism industry. We have been focused on technology and product development while adjusting the cost base to the current economic reality. Our rental fleet grew by 10% and we achieved our second largest underlying net profit after tax ($51.8m), although that was well behind the result we expected at the start of the year. Our operational practices have improved and our commitment to ESG has continued to be recognised positively in the market. Biggest business challenges in 2025? Heading into 2025, we see several challenges which we are ready to tackle:Investigation of disappearance of children in Ecuador was delayed for days despite video evidence
JERUSALEM (AP) — Israel’s attorney general has ordered police to open an investigation into Prime Minister Benjamin Netanyahu’s wife on suspicion of harassing political opponents and witnesses in the Israeli leader’s corruption trial. The Israeli Justice Ministry made the announcement in a terse message late Thursday., saying the investigation would focus on the findings of a recent report by the “Uvda” investigative program into Sara Netanyahu. The program uncovered a trove of WhatsApp messages in which Mrs. Netanyahu appears to instruct a former aid to organize protests against political opponents and to intimidate Hadas Klein, a key witness in the trial. The announcement did not mention Mrs. Netanyahu by name, and the Justice Ministry declined further comment. But earlier Thursday, Netanyahu blasted the Uvda report as “lies.”Seizure of Cook Islands-registered ship over alleged sabotage 'creates a bad look' for NZ - expert